Telehealth MAT After COVID: What's Here to Stay

The pandemic forced healthcare to evolve overnight. For people seeking medication-assisted treatment (MAT) for opioid use disorder, those emergency changes didn't just expand access — they fundamentally reshaped what treatment could look like. Now, years after those initial emergency flexibilities, we can see clearly what worked, what stuck, and what the future of addiction care looks like.

The transformation wasn't just about video appointments. It was about rethinking decades-old assumptions about who deserves access to care and how that care should be delivered.

This post explores the barriers that existed before COVID-19, the emergency policies that changed everything, what the data shows about telehealth outcomes, which changes have become permanent law, and what advocates are still fighting for.

The Pre-Pandemic Landscape: Barriers to MAT Access

Before March 2020, accessing medication-assisted treatment meant navigating a maze of regulatory hurdles that had little to do with medical necessity and everything to do with outdated drug war policies.

The X-waiver requirement forced physicians to complete special training and apply for a federal waiver just to prescribe buprenorphine (the active ingredient in Suboxone). Even after getting the waiver, doctors faced patient limits — starting at 30 patients, then expanding to 100 or 275 with additional requirements. This artificial cap meant qualified physicians routinely turned away patients who desperately needed help.

In-person requirements created impossible barriers for rural communities, people without transportation, those balancing work schedules, and anyone dealing with the physical and emotional toll of active addiction. A patient in rural Ohio might face a two-hour drive to the nearest MAT provider. Missing work for appointments meant risking your job. Having no car meant having no treatment.

The result? According to SAMHSA data, less than 20% of people with opioid use disorder received any form of MAT before the pandemic. The treatment existed, the medications were proven effective, but the system made access nearly impossible for the people who needed it most.

Emergency Flexibilities: The COVID-19 Policy Shift

In March 2020, as the pandemic forced society to rethink everything about in-person services, federal agencies issued emergency guidance that would fundamentally change addiction treatment.

The DEA announced that practitioners could prescribe buprenorphine via telehealth without an in-person examination. This wasn't a minor tweak — it eliminated the biggest access barrier overnight. Suddenly, a person experiencing withdrawal could connect with a provider the same day from their phone. No transportation needed. No waiting room stigma. No delay between crisis and care.

SAMHSA issued guidance allowing opioid treatment programs (OTPs) to provide take-home methadone doses for stable patients, reducing the daily clinic visit burden that made methadone treatment incompatible with employment or family responsibilities for many people.

Medicare and Medicaid rapidly expanded telehealth coverage for behavioral health services, including MAT, removing payment barriers that had previously limited virtual care. Most private insurers followed suit within weeks.

The changes were framed as temporary emergency measures. But within months, providers and patients alike realized these weren't just stopgap solutions — they were better than what existed before.

What the Data Shows: Telehealth MAT Outcomes

When emergency flexibilities expanded telehealth access to MAT, skeptics worried about treatment quality and diversion risk. The data from millions of telehealth encounters over the past six years tells a different story.

Treatment retention improved. Multiple studies found that patients initiating buprenorphine treatment via telehealth had equal or better retention rates compared to traditional in-person care. A 2023 JAMA study found 12-month retention rates of 68% for telehealth MAT versus 62% for in-person — likely because telehealth eliminated transportation and scheduling barriers that cause treatment dropout.

Access expanded dramatically. Between 2020 and 2024, the number of buprenorphine prescribers increased by 47%, with the largest gains in rural counties and historically underserved communities. Counties with no MAT providers before the pandemic saw new prescribers enter the field once they could serve patients virtually.

Diversion concerns didn't materialize. State prescription monitoring program data showed no increase in buprenorphine diversion during the telehealth expansion. The feared flood of illicitly diverted medication never happened — because people who get consistent, accessible treatment don't need to seek medications on the street.

Outcomes matched in-person care. Research consistently showed that patients receiving telehealth MAT had similar rates of negative drug screens, employment stability, and quality of life improvements as those receiving traditional in-person treatment. The medication worked the same. The therapeutic relationship formed just as effectively through video as across a desk.

For patients like those we serve at Grata Health in Virginia, Ohio, and Pennsylvania, these aren't just statistics — they're proof that accessible treatment saves lives.

Permanent Changes: What's Now Written Into Law

The question shifted from "should we allow telehealth MAT?" to "how do we make sure these changes don't disappear when the emergency ends?" Advocates, providers, and patients pushed Congress to codify what worked.

The Consolidated Appropriations Act of 2023 included the Mainstreaming Addiction Treatment (MAT) Act, which eliminated the X-waiver requirement entirely effective December 29, 2022. Any DEA-registered practitioner with a standard controlled substance license can now prescribe buprenorphine — no special waiver, no patient caps, no additional bureaucracy. This change alone is projected to double the prescriber workforce over the next decade.

The Consolidated Appropriations Act of 2023 also extended telehealth flexibilities for Medicare through December 31, 2024, then extended again through 2025 and 2026 in subsequent legislation. As of 2026, these flexibilities have been made permanent for behavioral health services, including MAT. You can read more about current regulations in our guide to federal telehealth policy updates.

State legislatures followed suit. Virginia, Ohio, and Pennsylvania all passed laws permanently allowing buprenorphine initiation via telehealth without prior in-person visits, with varying requirements around follow-up care and prescriber registration. You can learn more in our overview of state telehealth laws.

The DEA proposed permanent rules in 2024 that would allow telehealth prescribing of buprenorphine for new patients without an in-person visit, though with some guardrails around prescriber registration and audio-visual requirements. While not finalized until 2025, these rules signal federal commitment to maintaining expanded access.

The legal landscape isn't perfect — some states still impose unnecessary restrictions, and coverage gaps remain — but the core principle is now established: telehealth is legitimate, effective addiction treatment, not a temporary workaround.

Get started with telehealth MAT through Grata Health. Same-day appointments available, most insurance accepted.

Ongoing Advocacy: What We're Still Fighting For

While permanent telehealth flexibilities represent massive progress, advocates continue pushing for fuller access and equity in treatment availability.

Audio-only prescribing remains a contested issue. Current federal rules require video for buprenorphine prescribing, but this creates barriers for patients without smartphones or reliable internet. Some states allow audio-only visits; others don't. Advocates argue that a phone call is better than no treatment, especially for rural and low-income populations.

Interstate licensure still limits access. A doctor licensed in Virginia can't treat a patient who lives in Ohio, even via telehealth. While some interstate compacts exist for mental health providers, MAT prescribing remains bound by state-by-state licensing. This particularly affects border communities and people who move frequently.

Take-home methadone policies have largely reverted to pre-pandemic restrictions, with most OTPs returning to daily observed dosing for new patients. Advocates point to the safety and retention data from pandemic-era take-home allowances and push for permanent expansion of take-home privileges for stable patients.

Coverage parity remains uneven. While most insurers now cover telehealth MAT, some still impose higher copays for virtual visits or limit the number of telehealth appointments allowed per year. Federal and state insurance parity laws are supposed to prevent this, but enforcement is inconsistent.

Technology equity hasn't caught up to policy change. Many people lack smartphones, stable internet, or private spaces for video appointments. Some providers have adapted by offering audio-only visits or in-person options, but the digital divide still excludes vulnerable populations from fully benefiting from telehealth expansion.

The fight isn't over — it's just shifted from "allow telehealth" to "make telehealth truly accessible for everyone who needs it."

Lessons Learned: What COVID Taught Us About Access

The pandemic forced us to confront uncomfortable truths about how we'd designed addiction treatment. The emergency policies that expanded access didn't create new risks — they exposed how unnecessary the old barriers were.

Geography shouldn't determine access. A person in rural Pennsylvania deserves the same treatment options as someone in Philadelphia. Telehealth makes that possible in ways brick-and-mortar clinics never could.

Bureaucracy isn't safety. The X-waiver didn't protect patients — it just reduced the number of doctors willing to prescribe buprenorphine. Eliminating it expanded access without increasing diversion or harm.

Trust patients and providers. The assumption that people would abuse telehealth prescribing, or that doctors would recklessly hand out medications, didn't match reality. When you remove barriers and make treatment accessible, most people engage with it responsibly because they want to get better.

Flexibility improves outcomes. Allowing patients to attend appointments from home, receive medications by mail, and access care on their schedule doesn't compromise treatment quality — it enhances it by removing the logistical barriers that cause dropout.

The COVID-19 telehealth expansion wasn't perfect. Not everyone had equal access to technology. Some patients still preferred in-person care. Rural broadband gaps persisted. But the overall lesson was clear: when we remove unnecessary barriers, more people get treatment, more people stay in treatment, and more people recover.

What This Means for You: Accessing Telehealth MAT Today

If you're considering medication-assisted treatment, you have more options now than ever before. The emergency flexibilities that started in 2020 have evolved into permanent, accessible systems of care.

You can start treatment from home. No need to find transportation to a clinic for your first appointment. If you're experiencing withdrawal, you can connect with a provider the same day via video or phone and begin treatment immediately. Learn more about how online Suboxone treatment works.

You don't need to choose between work and treatment. Telehealth appointments fit into lunch breaks, early mornings, or evenings. You're not choosing between keeping your job and getting care — you can do both.

Most insurance covers it. Medicare, Medicaid, and most private insurance plans now cover telehealth MAT at the same rate as in-person visits. If you have Medicaid, Aetna, BCBS, Cigna, or Humana, telehealth treatment is likely fully covered.

The medication is the same. Whether prescribed via telehealth or in-person, buprenorphine works identically. The therapeutic relationship, the medical monitoring, the treatment planning — all transfer effectively to virtual care. Many patients report that the comfort and privacy of home actually makes it easier to be open and honest with their provider.

You're not alone in choosing telehealth. Millions of people now receive high-quality addiction treatment via telehealth. The data shows it works. The laws support it. The insurance covers it. What was once an emergency measure is now simply how modern healthcare works.

At Grata Health, we've treated thousands of patients across Virginia, Ohio, and Pennsylvania using the telehealth model that emerged from the pandemic. We've seen firsthand how removing barriers saves lives.

The Future of Telehealth MAT

Looking ahead, telehealth isn't replacing traditional in-person care — it's expanding the menu of options so everyone can find what works for them.

Hybrid models are emerging. Many patients start treatment via telehealth for convenience and accessibility, then transition to periodic in-person visits for lab work or longer check-ins, while maintaining routine appointments virtually. This flexibility matches how people actually live and work.

Technology continues improving. Secure messaging, app-based check-ins, remote monitoring tools, and AI-assisted screening are enhancing the telehealth experience while maintaining privacy and clinical effectiveness. What felt awkward on Zoom in 2020 now feels like natural, effective healthcare.

Access will keep expanding. As more states remove licensing barriers and more providers enter the field, underserved communities will gain access to specialists who were previously hundreds of miles away. A patient in rural Ohio might video-consult with an addiction specialist in Columbus who works with a local primary care doctor for in-person components.

The evidence base will grow. We're now tracking outcomes over years, not just months. Long-term retention data, quality of life measures, cost-effectiveness analyses — all will continue building the case for telehealth as standard of care.

Advocacy will shift focus. As basic telehealth access becomes normal, advocates will push harder on the remaining barriers: interstate licensure, audio-only access, technology equity, and ensuring underserved populations benefit equally from expanded access.

The pandemic forced innovation. What we learned is that the old system wasn't protecting anyone — it was just making treatment harder to access. The changes that stuck are the ones that should have existed all along.

Moving Forward: Treatment That Meets You Where You Are

The COVID-19 pandemic was a tragedy that changed everything about how we live, work, and receive healthcare. But in the rubble of that disruption, we built something better for addiction treatment.

We learned that a person struggling with opioid use disorder doesn't need more hoops to jump through — they need a doctor, a medication, and support. We learned that video visits work just as well as office visits for most people, most of the time. We learned that expanding access doesn't create chaos; it creates opportunity for healing.

The telehealth flexibilities that started as emergency measures have become permanent because they worked. Treatment retention improved. Access expanded. Outcomes matched in-person care. The feared risks never materialized.

If you've been putting off seeking help because you couldn't imagine fitting appointments into your life, or you live far from a clinic, or you just wanted privacy and comfort while starting treatment — those barriers are largely gone now. The system has changed. Treatment can meet you where you are.

You don't need to wait for the perfect moment or the perfect circumstances. The barriers that existed before COVID have been permanently lowered. Treatment is more accessible, more flexible, and more effective than ever before.

Start your recovery journey today with Grata Health. Telehealth appointments available across Virginia, Ohio, and Pennsylvania, with same-day starts and insurance accepted.